v3.26.1
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Loss Per Common Share
The following table reflects the calculation of basic and diluted loss per common share (in thousands, except per share amounts):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Net loss per ImmunityBio common share – basic and diluted
Numerator:
Net loss attributable to ImmunityBio common stockholders$(230,378)$(92,555)$(863,160)$(222,201)
Denominator:
Weighted-average number of common shares outstanding –
   basic and diluted
1,050,070 888,216 1,038,536 870,786 
Net loss per ImmunityBio common share – basic and diluted$(0.22)$(0.10)$(0.83)$(0.26)
Summary of Securities Excluded from the Computation of Potentially Dilutive Securities The following table details the number of shares of common stock underlying those securities that were excluded from the computation of weighted-average number of common shares outstanding – diluted (shares in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Related-party convertible note88,447 93,053 88,447 93,053 
Outstanding third-party warrants47,862 35,424 47,862 35,424 
Outstanding stock options23,559 25,931 23,559 25,931 
Outstanding RSUs5,931 9,055 5,931 9,055 
Outstanding related-party warrants1,638 1,638 1,638 1,638 
Total167,437 165,101 167,437 165,101